Global Brain Tumor Treatment Market Report and Forecast 2024-2032

Global Brain Tumor Treatment Market Outlook

The global brain tumor treatment market reached a value of about USD 3.44 billion in 2023. The market is further expected to grow at a CAGR of about 10.9% during the forecast period of 2024-2032 to attain a value of around USD 8.72 billion by 2032.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Brain Tumor: Insights and Diagnostic

Brain tumor is among the less common types of cancer, accounting for nearly 2% of the cancers. While the incidence is lower than the other types, it is extremely difficult to treat, which makes it among the top five fatal diseases. For the treatment, it is important to locate the exact location of the tumor and its growth. The location of the tumor is important because it defines the difficulty level of the treatment.

The prevalence of brain cancer is on a rise, nearly 400,000 new cases are diagnosed every year, which is further necessitating the demand for the treatment market. Brain tumors can be of different grades and these grades can be segmented into grade 1, 2, 3, and 4. While grade 1 and 2 are low grade tumors, grades 3 and 4 are high-grade and could be fatal. These cancers can be of two types-non-cancerous (benign) brain tumors and cancerous (malignant) brain tumors.

The common symptoms of the disease include headaches, nausea, seizures or fits, changes in mental health and behaviour, partial paralysis, issues with vision or speech.

Market Segmentations

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Brain tumor refers to the abnormal growth of cells in the brain. These brain tumors can be of different types and sizes. Some can be benign or non-cancerous, while others can be malignant or cancerous. Some cancers begin in the brain and spread to the rest of the body and some cancers develop in other body parts and then reach the brain as secondary tumors. 

Market by Treatment Method

• Targeted Therapy

• Chemotherapy

• Immunotherapy

• Others

Market Breakup by Indication

• Pituitary Tumors

• Meningioma

• Glioblastoma

• Others

Market Breakup by Treatment Channel

• Public

• Private

Market Breakup by Region

• North America
  • United States of America
  • Canada
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
• Asia Pacific
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Others
• Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Epidemiology of Brain Tumor

Brain tumor is a life-threatening disease. The epidemiology of brain tumor depends on various factors, including age and sex. The prevalence rate of the disease is fairly higher in men than women. However, the prevalence of non-malignant brain tumors is much higher in women than men, almost double. According to the recent data by American Cancer Society, the number of tumor cases, both primary and other tumors in the nervous system, in the United States was estimated to be around 24,160 with expected death count of 19,720. The tumor is more likely to occur in people above the age of 65. 

Therapeutic Landscape

The type of therapy/treatment that the patient goes through depends on the type and grade of the tumor. The methods in  brain tumor treatment market include surgery, chemotherapy, radiation therapy, targeted drug therapy, tumor treating fields, regular follow-up care and rehabilitation, among others. The most common treatment methods are as follows: 

Targeted Therapy- This treatment attacks/targets the specific genes, proteins, or the tissue environment with the use of medicines. The two most preferred targeted therapies include Bevacizumab (Avastin, Mvasi), which is an anti-angiogenesis therapy, and Larotrectinib (Vitrakvi) and entrectinib (Rozlytrek), which leads to genetic change.

Chemotherapy – This treatment method is preferred for faster growing tumors where the blast rate is higher. The therapy comprises of drugs which are given either through veins or orally, depending on the state of the patient. Brain tumors like medulloblastoma and lymphoma respond much better to chemotherapy than others, however, there have been cases of other tumors where the drugs are not able to make it to the tumor or the brain. There are several chemo drugs which are currently used in the therapy, either alone or in combination with one another. These drugs include Cisplatin, Carmustine (BCNU), Cyclophosphamide, Etoposide, Carboplatin, Irinotecan, Methotrexate, Lomustine (CCNU), Procarbazine, and Temozolomide, among others.

Immunotherapy- This therapy stimulates the body’s immune system to attack the tumor cells to inhibit their growth.  T cells, which are a type of immune cells, play a pivotal role in attacking the tumor cells in the brain. Immunotherapy aims at targeting and eliminating the cancer cells by activating anti-tumor response in the T cells. This method also helps in preventing relapse. 

Clinical Trials

Reduced Craniospinal Radiation Therapy- This trial is currently in phase II and studies the effects of reduced doses of radiation therapy and chemotherapy in patients with WNT/Wingless (WNT)-driven medulloblastoma, a new type of brain tumor that has been recently discovered. The reduced doses can help attack the tumor cells without the same intensity of the side-effects that normally occur due to the heavy dosage of drugs used in these therapies, including difficulty in learning, reduced hormones, or problems in doing daily activities. 

Early Response to Bevacizumab in Patients with Recurrent Glioblastoma- This study is also in phase II currently.  It studies the effectiveness of dynamic susceptibility contrast-enhanced magnetic resonance imaging (DSC-MRI) in calculating the rCBV or relative cerebral blood volume for fast response to bevacizumab in patients with recurrent glioblastoma.  

There are other ongoing clinical trials in the treatment market which are still under process and will likely be approved in the coming years.

Key Players in the Global Brain Tumor Treatment Market

The report gives a detailed analysis of the following key players in the global brain tumor treatment market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

• Pfizer Inc.

• Novartis AG 

• Merck & Co. Inc.

• AstraZeneca Plc.

• F. Hoffmann-La Roche Ltd.

• Amgen Inc.

• CordenPharma International

• Eisai Co., Ltd.

• Emcure Pharmaceuticals Limited

• Y-mAbs Therapeutics

• Bayer AG

• Bristol-Myers Squibb Co.

• GlaxoSmithKline Plc.

• Johnson & Johnson Services Inc.

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.

Key Highlights of the Report